McKesson (NYSE:MCK) Releases FY21 Earnings Guidance

McKesson (NYSE:MCK) updated its FY21 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $13.95-14.75 for the period, compared to the Thomson Reuters consensus estimate of $15.48. The company issued revenue guidance of +2-4% to $218.6-222.9 billion, compared to the consensus revenue estimate of $234.49 billion.McKesson also updated its FY 2021
Pre-Market guidance to 13.95-14.75 EPS.

Several brokerages have recently issued reports on MCK. Deutsche Bank raised their price objective on McKesson from $153.00 to $173.00 and gave the stock a hold rating in a research note on Wednesday, February 5th. Barclays reduced their price target on McKesson from $170.00 to $163.00 and set an equal weight rating for the company in a research report on Tuesday, March 31st. ValuEngine cut McKesson from a sell rating to a strong sell rating in a research report on Friday, May 1st. Guggenheim upgraded McKesson from a neutral rating to a buy rating in a research report on Friday, March 13th. Finally, Credit Suisse Group assumed coverage on McKesson in a research report on Wednesday, April 22nd. They set a neutral rating and a $146.00 price target for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the stock. The company has an average rating of Hold and an average target price of $163.82.

Shares of NYSE:MCK opened at $144.63 on Wednesday. The company has a debt-to-equity ratio of 1.33, a current ratio of 0.98 and a quick ratio of 0.56. The business’s 50 day moving average price is $135.39 and its 200-day moving average price is $142.72. The firm has a market capitalization of $25.24 billion, a PE ratio of -29.58, a P/E/G ratio of 1.55 and a beta of 0.82. McKesson has a 1 year low of $112.60 and a 1 year high of $172.18.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.10 by $0.17. The firm had revenue of $58.54 billion for the quarter, compared to analyst estimates of $55.60 billion. McKesson had a positive return on equity of 36.40% and a negative net margin of 0.41%. The business’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.69 earnings per share. As a group, analysts expect that McKesson will post 14.76 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date of this dividend is Friday, May 29th. McKesson’s dividend payout ratio (DPR) is currently 12.09%.

In other McKesson news, CEO Brian S. Tyler sold 4,063 shares of the business’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $135.00, for a total transaction of $548,505.00. Following the transaction, the chief executive officer now owns 16,255 shares of the company’s stock, valued at $2,194,425. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 8,187 shares of company stock worth $1,064,057 in the last three months. 0.88% of the stock is currently owned by corporate insiders.

About McKesson

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

See Also: How to use beta for portfolio diversification

Earnings History and Estimates for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with's FREE daily email newsletter.

Leave a Reply